摘要
1型糖尿病(T1DM)是器官特异性的自身免疫病,目前临床中缺乏T1DM的根治手段。内质网应激是早期T1DM发病的重要病理特征和促进其发生发展的重要因素,病理性的内质网应激是治疗T1DM的新靶标,靶向病理性内质网应激的药物有利于恢复胰岛β细胞的数量和质量,从而治疗T1DM。当胰岛β细胞中内质网出现错误折叠蛋白累积时会引起内质网应激,进而过度激活未折叠蛋白反应的3条经典通路:肌醇需求酶1、蛋白激酶R样内质网激酶和转录激活因子6通路。本文对基于这3条通路和未折叠或错误折叠蛋白为标靶治疗T1DM的药物研究进展作一综述。
Type 1 diabetes mellitus(T1DM)is an organ-specific autoimmune disease.Currently,there is a lack of radical treatment for T1DM.Endoplasmic reticulum stress is an important pathological feature of the early onset of T1DM and an important factor promoting its occurrence and development.Pathological endoplasmic reticulum stress is a new target for the treatment of T1DM.Drugs targeting pathological endoplasmic reticulum stress are conducive to restoring the quantity and quality of pancreaticβcells,so as to treat T1DM.Accumulation of misfolded proteins in the endoplasmic reticulum in isletβcells induces endoplasmic reticulum stress,which in turn activates three classical pathways of excessive unfolded protein response:inositol-requiring enzyme 1,proteinkinase R-like endoplasmic reticulum kinase,and activating transcription factor-6 pathways.This article reviews the progress of drug research targeting these three pathways and folded or misfolded proteins for the treatment of T1DM.
作者
张子洋
王莉
陈春麟
张梦军
ZHANG Ziyang;WANG Li;CHEN Chunlin;ZHANG Mengjun(Teaching and Research Section of Pharmaceutical Analysis,College of Pharmacy,Army Medical University,Chongqing 400038,China;Teaching and Research Section of Immunology,Basic Medical College,Army Medical University,Chongqing 400038,China)
出处
《中国医药导报》
CAS
2023年第22期51-55,共5页
China Medical Herald
基金
国家自然科学基金资助项目(31771002、82071825、81871301)
陆军军医大学本科生科研培育项目(2021XBK12)。
关键词
1型糖尿病
内质网应激
未折叠蛋白反应
胰岛Β细胞
Type 1 diabetes mellitus
Endoplasmic reticulum stress
Unfolded protein response
Pancreaticβcells
